The influence of combined oral contraceptive pills on carbohydrate metabolism in healthy women and in women with PCOS - a systemic review
KeywordsHormonal Contraception, Contraceptives oral combined, Glucose Metabolism Disorders, Insulin Resistance, Glucose Intolerance
Introduction: Combined oral contraceptives (COCs) are a commonly used contraceptive method. They are used as one of the method therapy in women with PCOS. Outcomes from previous studies about the influence of the COCs on carbohydrate metabolism are diverse. Purpose: To assess the influence of combined oral contraceptives on parameters of carbohydrate metabolism in healthy women and in women with PCOS.
Review methods: We conducted a systemic review according to PRISMA protocol. Databases as Pubmed, Scopus, Web of Science were screened systematically.The inclusion criteria were:a study published in 2016-2021, which contains information about the change of carbohydrate parameters as: fasting insulin, fasting glucose levels;HOMA-IR;insulin, glucose levels etc.The participants were healthy/PCOS women. Studies conducted on animals were excluded. The final number of studies enrolled in this study is 15.
Abbreviated description of the state of knowledge: There are studies in which negative influences of the COCs on carbohydrate metabolism are proved. Nevertheless, many of these studies were conducted years ago.COCs, when they were introduced in 1960s, contained different compounds and amounts of hormones. Over the years a successive decrease in estrogen dose has occurred . Also progestogens have been developed in order to minimize the androgenic effects.Results of studies conducted nowadays are ambiguous.
Summary: A significant impairment of carbohydrate metabolism in short period of time was not detected in healthy women. In women with PCOS the results depended on the type of COCs used.
‘Contraception. Evidence brief’. https://www.who.int/publications-detail-redirect/WHO-RHR-19.18 (accessed May 22, 2022).
United Nations, Contraceptive Use by Method 2019: Data Booklet. UN, 2019. doi: 10.18356/1bd58a10-en.
D. B. Cooper, P. Patel, and H. Mahdy, ‘Oral Contraceptive Pills’, in StatPearls, Treasure Island (FL): StatPearls Publishing, 2022. Accessed: May 22, 2022. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK430882/
‘Family Planning - A global handbook for providers’. https://www.who.int/publications-detail-redirect/9780999203705 (accessed May 22, 2022).
U. J. Gaspard and P. J. Lefebvre, ‘Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease’, American Journal of Obstetrics and Gynecology, vol. 163, no. 1, Part 2, pp. 334–343, Jul. 1990, doi: 10.1016/0002-9378(90)90578-U.
R. N. Prasad, D. Liew, and S. S. Ratnam, ‘Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women’, Contraception, vol. 39, no. 1, pp. 21–35, Jan. 1989, doi: 10.1016/0010-7824(89)90013-9.
I. F. Godsland, C. Walton, C. Felton, A. Proudler, A. Patel, and V. Wynn, ‘Insulin resistance, secretion, and metabolism in users of oral contraceptives’, J Clin Endocrinol Metab, vol. 74, no. 1, pp. 64–70, Jan. 1992, doi: 10.1210/jcem.74.1.1530790.
V. Wynn et al., ‘Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism’, Lancet, vol. 1, no. 8125, pp. 1045–1049, May 1979, doi: 10.1016/s0140-6736(79)92949-0.
S. O. Skouby, O. Andersen, N. Saurbrey, and C. Kühl, ‘Oral contraception and insulin sensitivity: in vivo assessment in normal women and women with previous gestational diabetes’, J Clin Endocrinol Metab, vol. 64, no. 3, pp. 519–523, Mar. 1987, doi: 10.1210/jcem-64-3-519.
I. F. Godsland, D. Crook, and V. Wynn, ‘Low-dose oral contraceptives and carbohydrate metabolism’, Am J Obstet Gynecol, vol. 163, no. 1 Pt 2, pp. 348–353, Jul. 1990, doi: 10.1016/0002-9378(90)90580-z.
R. Sitruk-Ware and A. Nath, ‘Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills’, Best Pract Res Clin Endocrinol Metab, vol. 27, no. 1, pp. 13–24, Feb. 2013, doi: 10.1016/j.beem.2012.09.004.
W. R. Rowley, C. Bezold, Y. Arikan, E. Byrne, and S. Krohe, ‘Diabetes 2030: Insights from Yesterday, Today, and Future Trends’, Popul Health Manag, vol. 20, no. 1, pp. 6–12, Feb. 2017, doi: 10.1089/pop.2015.0181.
A. D. Deshpande, M. Harris-Hayes, and M. Schootman, ‘Epidemiology of diabetes and diabetes-related complications’, Phys Ther, vol. 88, no. 11, pp. 1254–1264, Nov. 2008, doi: 10.2522/ptj.20080020.
‘Prediabetes - Symptoms and causes’, Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/prediabetes/symptoms-causes/syc-20355278 (accessed May 22, 2022).
E. Diamanti-Kandarakis and A. Dunaif, ‘Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications’, Endocr Rev, vol. 33, no. 6, pp. 981–1030, Dec. 2012, doi: 10.1210/er.2011-1034.
A. Haverinen, M. Kangasniemi, K. Luiro, T. Piltonen, O. Heikinheimo, and J. S. Tapanainen, ‘Ethinyl estradiol vs estradiol valerate in combined oral contraceptives - Effect on glucose tolerance: A randomized, controlled clinical trial’, Contraception, vol. 103, no. 1, pp. 53–59, Jan. 2021, doi: 10.1016/j.contraception.2020.10.014.
M. Malara, A. Kęska, J. Tkaczyk, and G. Lutosławska, ‘Metabolic Profile In Active Female Students Users And Non-Users Combined Oral Contraceptives’, Annals of Applied Sport Science, vol. 8, no. 2, pp. 0–0, May 2020, doi: 10.29252/aassjournal.835.
S. Palacios, E. Colli, and P. A. Regidor, ‘Metabolic and laboratory effects of a progestin-only pill containing drospirenone 4 mg in comparison to desogestrel 75 µg: a double-blind, double-dummy, prospective, randomised study’, Eur J Contracept Reprod Health Care, vol. 26, no. 6, pp. 454–461, Dec. 2021, doi: 10.1080/13625187.2021.1957094.
C. Klipping et al., ‘Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone’, Contraception, vol. 103, no. 4, pp. 213–221, Apr. 2021, doi: 10.1016/j.contraception.2021.01.001.
Q. Wang et al., ‘Effects of hormonal contraception on systemic metabolism: cross-sectional and longitudinal evidence’, Int J Epidemiol, vol. 45, no. 5, pp. 1445–1457, Oct. 2016, doi: 10.1093/ije/dyw147.
M.-E. Mosorin et al., ‘Current use of combined hormonal contraception is associated with glucose metabolism disorders in perimenopausal women’, Eur J Endocrinol, vol. 183, no. 6, pp. 619–626, Dec. 2020, doi: 10.1530/EJE-20-0406.
O. N, ‘Association Between Oral Contraceptive use and Some Biochemical Changes in Saudi Women’, Bioscience Biotechnology Research Communications, vol. 13, pp. 1699–1707, Dec. 2020, doi: 10.21786/bbrc/13.4/11.
J. Vrbíková and D. Cibula, ‘Combined oral contraceptives in the treatment of polycystic ovary syndrome’, Hum Reprod Update, vol. 11, no. 3, pp. 277–291, Jun. 2005, doi: 10.1093/humupd/dmi005.
D. Glintborg, H. Mumm, J. J. Holst, and M. Andersen, ‘Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome’, Endocr Connect, vol. 6, no. 4, pp. 267–277, May 2017, doi: 10.1530/EC-17-0034.
Q.-Y. Wang, Y. Song, W. Huang, L. Xiao, Q.-S. Wang, and G.-M. Feng, ‘Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial’, Chin Med J (Engl), vol. 129, no. 8, pp. 883–890, Apr. 2016, doi: 10.4103/0366-6999.179783.
A. Podfigurna, B. Meczekalski, F. Petraglia, and S. Luisi, ‘Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone)’, J Endocrinol Invest, vol. 43, no. 4, pp. 483–492, Apr. 2020, doi: 10.1007/s40618-019-01133-3.
M. Namli Kalem et al., ‘Effect of combined oral contraceptive use on serum 25-hydroxy vitamin D levels and ultrasound parameters in patients with polycystic ovary syndrome’, Gynecol Endocrinol, vol. 32, no. 4, pp. 281–284, 2016, doi: 10.3109/09513590.2015.1113251.
M. V. De Diego et al., ‘Metabolic impact of current therapeutic strategies in Polycystic Ovary Syndrome: a preliminary study’, Arch Gynecol Obstet, vol. 302, no. 5, pp. 1169–1179, Nov. 2020, doi: 10.1007/s00404-020-05696-y.
S. Bodur, O. Dundar, M. Kanat-Pektas, M. F. Kinci, and L. Tutuncu, ‘The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: A randomızed controlled study’, Taiwan J Obstet Gynecol, vol. 57, no. 3, pp. 411–416, Jun. 2018, doi: 10.1016/j.tjog.2018.04.015.
M. Amiri, F. Ramezani Tehrani, F. Nahidi, A. Kabir, F. Azizi, and E. Carmina, ‘Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproterone acetate with third generation progestins’, Metabolism, vol. 73, pp. 22–35, Aug. 2017, doi: 10.1016/j.metabol.2017.05.001.
S. M. Bhattacharya, A. Jha, and L. DasMukhopadhyay, ‘Comparison of two contraceptive pills containing drospirenone and 20 μg or 30 μg ethinyl estradiol for polycystic ovary syndrome’, International Journal of Gynecology & Obstetrics, vol. 132, no. 2, pp. 210–213, 2016, doi: 10.1016/j.ijgo.2015.06.065.
L. S. Silva-Bermudez et al., ‘Effects of oral contraceptives on metabolic parameters in adult premenopausal women: a meta-analysis’, Endocr Connect, vol. 9, no. 10, pp. 978–998, Oct. 2020, doi: 10.1530/EC-20-0423.
M. Amiri, F. Nahidi, R. Bidhendi-Yarandi, D. Khalili, M. Tohidi, and F. Ramezani Tehrani, ‘A comparison of the effects of oral contraceptives on the clinical and biochemical manifestations of polycystic ovary syndrome: a crossover randomized controlled trial’, Hum Reprod, vol. 35, no. 1, pp. 175–186, Jan. 2020, doi: 10.1093/humrep/dez255.
L. M. Lopez, D. A. Grimes, and K. F. Schulz, ‘Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus’, Cochrane Database Syst Rev, vol. 2019, no. 11, Nov. 2019, doi: 10.1002/14651858.CD006133.pub5.
L. Chasan-Taber et al., ‘A prospective study of oral contraceptives and NIDDM among U.S. women’, Diabetes Care, vol. 20, no. 3, pp. 330–335, Mar. 1997, doi: 10.2337/diacare.20.3.330.
R. J. Troisi, C. C. Cowie, and M. I. Harris, ‘Oral contraceptive use and glucose metabolism in a national sample of women in the united states’, Am J Obstet Gynecol, vol. 183, no. 2, pp. 389–395, Aug. 2000, doi: 10.1067/mob.2000.105909.
S. H. Oguz and B. O. Yildiz, ‘An Update on Contraception in Polycystic Ovary Syndrome’, Endocrinol Metab (Seoul), vol. 36, no. 2, pp. 296–311, Apr. 2021, doi: 10.3803/EnM.2021.958.
A. Stelmaszyk, J. Domagała, and M. Dworacka, ‘Znaczenie składu hormonalnych środków antykoncepcyjnych dla ich skuteczności i tolerancji’, Forum Medycyny Rodzinnej, vol. 11, no. 3, Art. no. 3, 2017.
R. M. Krauss and R. T. Burkman, ‘The metabolic impact of oral contraceptives’, Am J Obstet Gynecol, vol. 167, no. 4 Pt 2, pp. 1177–1184, Oct. 1992, doi: 10.1016/s0002-9378(12)90408-1.
J. Brynhildsen, ‘Combined hormonal contraceptives: prescribing patterns, compliance, and benefits versus risks’, Ther Adv Drug Saf, vol. 5, no. 5, pp. 201–213, Oct. 2014, doi: 10.1177/2042098614548857.
I. J. Halperin, S. S. Kumar, D. F. Stroup, and S. E. Laredo, ‘The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies’, Hum Reprod, vol. 26, no. 1, pp. 191–201, Jan. 2011, doi: 10.1093/humrep/deq301.
A. Kriplani, A. J. Periyasamy, N. Agarwal, V. Kulshrestha, A. Kumar, and A. C. Ammini, ‘Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome’, Contraception, vol. 82, no. 2, pp. 139–146, Aug. 2010, doi: 10.1016/j.contraception.2010.02.009.
How to Cite
Copyright (c) 2022 Katarzyna Wicha, Rafał Wierciszewki, Aleksandra Pokarowska, Anna Hawryluk, Beata Pająk
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 213
Number of citations: 0